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True North: Building Imaginary Worlds with the Revised Canadian (CADTH) Guidelines for 
Health Technology Assessment 
Paul C Langley, PhD, Adjunct Professor, University of Minnesota 
 
Abstract 
In March 2017 the Canadian Agency for Drugs and Technologies in Health (CADTH) released the 4th edition of their Guidelines for the 
Economic Evaluation of Health Technologies: Canada. These guidelines, which were first published and revised for a 3rd edition in 2006 
are intended to help decision makers, health systems leaders and policy makers make well-informed decisions. They are designed, 
apparently, to support best practice in conducting health technology assessments in Canada. The purpose of this commentary is to 
consider whether or not the evidence standards proposed and the consequent modeled claims for economic effectiveness meet the 
standards of normal science: are the CADTH standards capable of generating claims for competing products that are credible, evaluable 
and replicable? The review argues that the standards proposed by CADTH do not meet the standards expected in normal science. 
Technical sophistication in building reference case imaginary worlds is not a substitute for claims that are experimentally evaluable or 
capable of assessment through systematic observation. There is no way of judging whether imaginary claims are right or even if they 
are wrong. CADTH is not alone in setting standards that fail to meet the standards of normal science. Recent commentaries on 
formulary submission guidelines in a number of other countries, to include Ireland, the Netherlands, France, Australia, the UK and New 
Zealand conclude that they are subject to the same criticism. If the CADTH guidelines were never intended to support feedback to health 
system decision makers, then this should be made clear. If not, then consideration should be given to withdrawing the guidelines to 
ensure they conform to these standards. Hopefully, future versions of the CADTH guidelines will address this issue and focus on a 
rigorous research program of claims assessment and feedback and not the building of imaginary worlds. 
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Introduction 
Canada, in common with countries including the UK, Ireland, 
the Netherlands, New Zealand and Australia, has issued 
guidelines to support formulary submissions 1 2 3 4 5 6. In the US 
recommendations for formulary submission standards have 
been proposed by the Academy of Managed Care Pharmacy 
(AMCP) together with modelling standards proposed by the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) 7 8 9. Guidelines have also been proposed as 
a standard for the European Union under the EUnetHTA 
umbrella 10. A common feature of many of these guidelines, as 
in the Canadian case, is to mandate a cost-utility reference 
case for the modeling of disease interventions, with particular 
reference to chronic disease.  
 
Previous publications and a number of formulary evaluation 
commentaries in this series have made clear that in putting to 
one side a commitment to the standards of normal science, in 
which modeled claims or hypotheses are credible, evaluable 
and replicable, decision makers in health care have a limited 
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evidence base for formulary decisions 11 12 13 14 15. A lifetime 
cost-per-QALY model is not designed to generate evaluable 
claims 16. It is a construct that is defended by its sufficient 
correspondence to a perceived reality. Validation focuses on 
the core model and its assumptions. Whether or not the model 
can support evaluable claims and whether or not these claims 
could ever be evaluated is apparently irrelevant. Indeed, in the 
draft of the present guidelines issued in October 2016 it was 
made quite clear that, from CADTH’s perspective: ‘Economic 
evaluations are designed to inform decisions. As such, they are 
distinct from conventional research activities, which are 
designed to test hypotheses’ 17 . This position continues to be 
held. The standards of normal science are not intended to 
apply to the modeled claims; hypothesis testing is explicitly 
rejected. 
 
In rejecting the standards of normal science, advocates of 
models that are intended to ‘inform’ decision makers in health 
care systems (whatever that means) rather than establish a 
practical research program, put to one side a commitment to 
standards that have been in place since the seventeenth 
century in favor of what may be described as pseudoscience: 
intelligent design rather than natural selection 18. In an effort 
to avoid this characterization, guidelines have been proposed 
by the Program in Social and Administrative Pharmacy at the 
University of Minnesota that reject imaginary constructs in 
favor of credible, evaluable and replicable claims; claims which 
apply equally well to clinical outcomes as well as those for 
comparative cost-effectiveness and budget impact 19. 
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Formulary submissions are to be supported by protocols to 
detail how the claims are to be evaluated and reported. This 
requirement is not new. It was put forward as a standard over 
ten years ago in formulary submission guidelines developed 
for the Wellpoint (now Anthem) health system in the US 20 21. 
In a recent overview of the 22 commentaries on health 
technology assessment published in INNOVATIONS in 
Pharmacy since mid-2016 the importance of distinguishing 
science from pseudoscience (a.k.a true bunk) was emphasized 
22. The concern is that technology assessment agencies persist 
in their commitment to the construction of imaginary worlds 
and ask decision makers to take them seriously.  
 
The purpose of this commentary is to review the standards 
proposed for health technology assessment in the 4th edition 
of the CADTH guidelines. The commentary adopts the same 
format as that followed in the reviews of other health 
technology assessment guidelines: (i) a brief overview of the 
structure and standards proposed; (ii) a discussion; and (iii) 
suggestions for possible revisions to the guidelines. Questions 
that are addressed are: do the guidelines support claims for 
new medicines or medicinal products that are credible, 
evaluable and replicable?  Are the guidelines capable of 
supporting a progressive research program of 
experimentation and systematic observation? Are the 
guidelines capable of supporting feedback on product 
performance to physicians, patients and health system 
decision makers?  
 
Guideline Structure 
The CADTH guidelines are intended to help decision makers, 
health systems leaders and policy makers make well informed 
decisions. They are designed to support best practice in 
conducting health technology assessments in Canada. The 
submission guidelines cover: 
• Guideline statements: summary points for the main 
sections 
• Section1: Decision Problem 
• Section 2: Types of Evaluations 
• Section 3: Target Population 
• Section 4: Perspective 
• Section 5: Time Horizon 
• Section 6: Discounting 
• Section 8: Modelling 
• Section 9: Effectiveness 
• Section 10: Measurement and valuation of health 
• Section 11. Resource Uses and Costs 
• Section 12: Analysis 
• Section 13: Uncertainty 
• Section 14: Equity 
• Section 15: Reporting  
• Appendix 1: Standard Reporting Format 
• Appendix 2: Reference Case (defined in terms of 
Sections 1 through 14). 
Section1: Decision Problem 
For the CADTH guidelines, economic evaluations are intended 
to inform decisions; they are not intended to test hypotheses. 
The decision problem entails identifying the perspective of the 
problem to be addressed together with the relevant costs and 
outcomes. The assessment should be comparative reflecting 
the variety of interventions relative to the decision problem. 
The time horizon should be identified for the specified costs 
and outcomes. Where relevant, sub-groups for the 
intervention should be identified. Reference Case: specify the 
interventions, setting, perspective, costs, outcomes, time 
horizon and target population. 
 
Section 2: Types of evaluations 
The recommended evaluation is generic cost-utility analysis. 
This is intended to allow broad comparisons across different 
conditions and interventions, facilitating resources based on 
maximizing health gains. However, the guidelines do not 
recommend or mandate a specific utility instrument.  The 
absence of a mandated specific instrument renders claims for 
cross disease and product areas difficult (if not impossible): 
different HRQoL instruments ‘can produce very different 
utilities for the same health state’. The guidelines recognize 
this limitation, but argue it speaks to the need for further 
methodological advances. Reference Case: Cost-utility analysis 
with outcomes captured as QALYs.   
 
Section 3: Target Population 
The submission should specify the target populations(s), 
together with their description. This should include patient 
characteristics, disease severity and grading, and the 
distribution of comorbid states. Models should address 
questions of heterogeneity in the target population and its 
quantitative impact. To avoid post hoc data dredging, robust 
evidence should be provided to justify sub-group analysis for 
more homogeneous target populations. Reference Case: 
Identify population(s) for intervention, stratified to distinct sub-
groups if necessary. 
 
Section 4: Comparators 
Comparators should be identified as part of the decision 
problem. Interventions currently used and potentially 
displaced should be identified together with interventions 
likely to be available in the near future. These should relate to 
the complete clinical pathway. If current technologies are of 
poor or uncertain value, best supportive care should be 
considered as inclusion as a comparator. Comparators could 
be management strategies intended to maximize impact of 
primary therapy. Comparators should be clearly identified to 
account for all relevant costs and outcomes. Reference case: 
All relevant interventions including current care.  
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Section 5: Perspective 
The perspective of the reference case is the publicly funded 
health care payer.  The costs should be those incurred by the 
Canadian public payer with all meaningful patient outcomes. 
These could include government programs and services 
beyond healthcare. Supplementary non-reference case 
analyses could accommodate wider and multiple perspectives. 
Reference case: Publicly funded health care payer.   
 
Section 6: Time Horizon 
The time horizon should be based on the condition and the 
likely impact of the intervention. In the reference case, the 
horizon should be long enough to capture all potential 
differences in costs and outcomes associated with the 
intervention. A longer term analysis allows for the exploration 
of uncertainty, but does not imply that primary data must be 
collected from patients or affected populations over this time 
period. In chronic conditions or when interventions have 
differential effects on mortality a lifetime horizon is most 
appropriate. If no long term differences, a shorter time line 
may be considered. Reference case: Long enough to capture all 
relevant differences in the future costs and outcomes 
associated with the intervention. 
 
Section 7: Discounting 
Costs and outcomes (utilities) over the timeframe of the model 
should be discounted at a rate of 1.5% per annum. Reference 
case: Costs and outcomes at a rate of 1.5% per annum. 
 
8. Modelling 
The model, where a probabilistic rather than a deterministic 
framework is preferred, should be consistent with the decision 
problem describing the clinical or care pathway. Choice of 
model is at the discretion of the manufacturer in representing 
the natural history of the target treating population. The 
model should be validated: face validity of the model 
structure, assumptions, data and results. Validation does not 
include empirical assessment (i.e., hypothesis testing) of 
modeled claims. No Reference case equivalent. 
 
9. Effectiveness 
A comprehensive search of data sources should be undertaken 
to inform estimates of effectiveness and harms: fitness for 
purpose, credibility and consistency. Justify surrogate end-
points. Capture uncertainty through reference case 
probabilistic analysis. No reference case equivalent. 
 
10. Measurement and Valuation of Health 
QALYs are the ‘gold standard’ value of the effect of an 
intervention, using health preferences from an indirect (i.e., 
multi-attribute) generic classification (EQ-5D-3L or EQ-5D-5L, 
HUI, SF-6D). Health preferences should reflect those of a 
general Canadian population. No preference for one measure 
over another. Reference case: Identify, measure and value all 
relevant health outcomes with Canadian population 
preferences from an indirect method of measurement. 
 
11. Resource Use and Costs   
 Should be based on Canadian sources with valuation from 
perspective of publicly funded health care payee. Data sources 
should be selected that reflect opportunity cost. If 
appropriate, broader societal impact should be captured in 
intervention impact on paid or unpaid work by patients and 
caregivers. Reference case: Estimate resource units and costs 
using jurisdiction of interest from perspective of public health 
care payer. 
 
12. Analysis 
Economic evaluation assessed based on incremental cost-
effectiveness ratio (ICER). In reference case typical application 
will be Monte Carlo probabilistic simulation. Reference case: 
Probabilistic sensitivity analysis with ICERs.   
 
13. Uncertainty 
Capture uncertainty through probabilistic analysis. Present 
results as cost-effectiveness acceptability curves and cost-
effectiveness acceptability frontiers. Structural uncertainty to 
be addressed through scenario analysis. Reference case: 
Compare to non-reference case analysis, apply cost-
effectiveness acceptability curves and acceptability frontiers. 
 
14. Equity 
All outcomes weighted equally. Describe fully relevant target 
populations. Reference case: Weight equally regardless of 
characteristics of those receiving or affected by intervention.  
 
15. Reporting 
Critical requirements are (i) transparency and (ii) description 
of quality assurance processes. No reference case equivalent. 
 
Discussion 
There is no requirement in the CADTH guidelines for claims for 
competing products to be presented that are credible, 
evaluable and replicable. Credible claims, in this context 
referring to their ability to be empirically evaluated not as 
outcomes that are judged credible because the model is 
considered to be sufficiently representative of the ‘real’ world. 
There is no intention in the guidelines that any modeled claim 
should be evaluable. This conclusion applies to models 
irrespective of whether or not they take a short-term or a long-
term or lifetime perspective. In these respects the CADTH 
guidelines are no different from those in Australia, or from 
those for the UK with the National Institute for Health and Care 
Excellence (NICE), Ireland, New Zealand and the Netherlands. 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                                2017, Vol. 8, No. 2, Article 9                            INNOVATIONS in pharmacy   4 
 
In common with the majority of other guidelines that have 
been reviewed, the CADTH guidelines mandate a reference 
case. This is similar to the reference case mandated by NICE 
but without the requirement for a preferred generic utility 
instrument (in the case of NICE the EQ-5D). The other key 
difference is the absence of any attempt to apply willingness-
to-pay thresholds for cost-per-QALY claims. As noted below, 
this is probably wise given the absence of a preferred utility 
instrument. 
 
Constructed Evidence 
Unfortunately, as noted in the case of the PBAC guidelines and 
others, in the absence of claims that are evaluable and 
replicable, there can be no assurance that they are credible. To 
argue that they are acceptable and can play a role in 
‘informing’ decision makers,  in the absence of any empirical 
evidence to support the claims, is to adopt a relativist position. 
Hypothesis testing of competing clinical claims and the cost-
effectiveness claims that rely upon them are, for CADTH, 
irrelevant to formulary decisions. Economic evaluations are 
not a research activity. Questions of the credibility of claims, 
including clinical claims, which one imagines include patient 
reported outcomes such as pain, satisfaction with care, side 
effects and even quality of life, can be put to one side even 
though these are essential to a composite claim for the 
effectiveness part of the cost-effectiveness model. There is no 
need, presumably, to consider the null hypothesis that there is 
no difference in patient reported outcomes between 
competing therapies? 
 
For a relativist evidence is never discovered, only constructed 
within a particular social community 23.  The community of 
pharmacoeconomists who accept a reference case paradigm 
to support imaginary claims for competing pharmaceutical 
products through ‘informing’ decision makers would, as 
relativists reject any arguments that one body of evidence is 
superior to another. A research program is not seen as one 
that generates new knowledge through claims evaluation and 
replication but one that is judged on its ability to persuade and 
mobilize community support for invented facts. Such a 
research program puts to one side any notion of the progress 
of science, of the process through which new evidence 
overturns consensus views, in favor of rhetoric and authority. 
Reference case imaginary modeling, the rejection of 
experiment through hypothesis testing or systematic 
observation, is seen as the ‘gold standard’. This acceptance of 
a gold standard to support the construction of imaginary 
worlds is in direct contrast to the motto of the Royal Society 
(founded 1660; Royal Charter 1662): nullius in verba (take no 
man’s word for it’) 24. As stated on the Royal Society website, 
this motto ‘is an expression of the determination of Fellows to 
withstand the domination of authority and to verify all 
statements by an appeal to facts determined by experiment’. 
This stricture applies equally well to the uncritical acceptance 
of clinical trials where there is little evidence for replication of 
results as well as to the constructed evidence and conclusions 
of long-term and lifetime economic models. Whether this is in 
the best interests of provincial authorities who may rely on 
CADTH assessments is a moot point. 
 
Rejecting constructed evidence to support therapeutic claims 
raises questions as to the relevance of technical standards for 
constructing long-term or lifetime models. The detail in the 
standards required by CADTH for modeling the imaginary 
world of the reference case points to a potential substantial 
misallocation of time and resources to justify a cost-utility 
model that at the end of the day supports unevaluable claims. 
  
Immunity to Failure 
While simulations can fail, lifetime cost-per-QALY modeled 
claims are immune to failure. Presumably, that is their 
attraction to both manufacturers and assessment agencies. 
The only basis on which a non-evaluable modeled claim can be 
challenged is on a review of the structure of the core model 
(e.g., state transition models) and the assumptions of the 
model (e.g., state transition probabilities). In practical terms, it 
is possible not only to build models that produce competing 
cost-per-QALY claims as well as models that reverse engineer 
to generate competing results. In both the UK and Australia 
models are subject to independent review and appraisal. The 
assessors may recommend structural changes to the core 
model or challenge the basis on which assumptions have been 
derived (e.g., attaching quality of life weights to therapy 
states). Presumably, the criterion employed is whether or not 
the appraisers consider the model is a ‘sufficient’ 
representation of the reality captured by the natural course of 
the disease and the impact of competing interventions. If it is 
judged ‘sufficient’ then the non-evaluable results necessarily 
follow. Further assessment is unnecessary. The model and its 
claims can then be forwarded for peer review and publication, 
joining the thousands of other non-evaluable cost-
effectiveness and cost-utility models that have been published 
over the past 30 years. 
 
If these unevaluable claims are intended to inform decision 
makers in health systems them CADTH should make clear to 
agencies such as provincial health authorities that they are 
only intended to do this. They are not intended to generate 
evaluable claims. The provincial health authorities can then 
decide whether this is a useful input to decision making or 
whether they should be put to one side in favor of a more 
rigorous and credible assessment protocol.  
 
Validation 
Irrespective of the extent to which model builders claim that 
their imaginary worlds are a valid construct and have a pivotal 
role to play in informing decision makers, the validation 
standards proposed in the CADTH guidelines make no claim for 
validation that involves prospective, protocol-driven  empirical 
evaluation in target treating populations. The validation 
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process, as reported in the submission is intended to cover 
internal validity, external validity and cross-validity. Where the 
question of external validity with actual data is addressed it is 
in terms of ‘whether the model estimates are consistent with 
other reliable and preferably independent data sources’; 
hypothesis testing is not seen as essential and if ‘the objective 
of the analysis is to make projections about the future, the 
validity of the model and the associated projections should be 
assessed as data become available’. Presumably, it is not a 
concern if these comparisons are impossible to make or if, in 
the future, these data are not available.  
 
In practice, validation for CADTH means demonstrating that 
*patients track though the model structure appropriately, 
typically following treatment guideline algorithms and stage 
evaluations for the timeline of disease progression, together 
with empirical justification of the model assumptions and 
choice of parameters and then comparing the model with 
similar models to assess comparability. The bottom line is a 
judgement of ‘sufficient’ correspondence to the assessor’s 
perception(s) of an unknown future reality. 
 
Cost-utility Analysis 
In the absence of a commitment to a protocol to evaluate 
claims expressed in cost-utility terms, the preference for 
utilities as an end-point (Section 3A.1) creates a further barrier 
to evaluation 25 . Utilities are not collected on a regular basis 
by health care systems as part, for example, of searchable 
electronic medical records to support systematic observation 
of outcomes for claims assessment. Given this, it seems odd 
that CADTH would focus on utilities as the preferred 
effectiveness measure as this would appear to guarantee that 
the outcome claims are (and always were intended to be) non-
evaluable. 
 
There is also the question of choice of utility measure or 
instrument and the possible need to crosswalk or map from 
one instrument to another. While the guidelines do not 
mandate a specific QALY measure, they do not recommend 
mapping from one instrument another. This means that, while 
generic QALYs are put forward as a gold standard for 
comparing outcomes across products and disease areas, thus 
‘facilitating resources based on maximizing health gains’ 
modeled imaginary claims that rest on disparate QALY 
measures mean that such a comparisons is impossible. This 
same objection would apply if CADTH wished to apply 
willingness-to-pay cost-per-QALY thresholds. 
 
Even if a single utility instrument is mandated, technology 
assessment agencies can still shoot themselves in the foot. 
Consider the NICE EQ-5D debacle. Concern with the sensitivity 
of the EQ-5D-3L to changes in the quality of life  led to 
introducing five levels rather than three of severity: (i) no 
problems: (ii) slight problems; (ii) moderate problems; (iv) 
severe problems; and (v) extreme problems rather than (i) no 
problems; (ii) some problems; and (iii) extreme problems. 
Unfortunately, the application of the EQ-5D is now in doubt as 
the attempt to move to a more sensitive version of the 
instrument with five levels within each health domain (EQ-5D-
5L) as opposed to the three levels (EQ-5D-3L) has led to a 
situation where these two versions produce substantially 
different estimates of cost-effectiveness 26. This is because of 
the combined effect of differences in the way individuals 
respond to the changed descriptive system and the changed 
valuation system in the 5L compared to the 3L. The two 
versions are not consistent with each other. This problem is 
likely to plague NICE for years given the number of accepted 
modeled evaluations and claims for cost-per-QALY outcomes 
based on the EQ-5D-3L.  
 
This result should not, in retrospect, have come as a surprise 
as there have always been difficulties in mapping between the 
various multi-attribute HRQoL instruments and comparing 
these to the more fundamental measures of standard gamble 
and time trade-off 27. It also raises the intriguing possibility 
that manufacturers, in their submissions to CADTH, could 
select from the various utility instruments, selecting the one 
that gave the ‘best’ results to support cost-effectiveness claims 
and pricing.  
 
Even if one accepts the case for non-evaluable ‘for information 
only’ imaginary claims, the CADTH reference cases stands or 
falls on the willingness to accept the manufacturers choice of 
a QALY measure. As CADTH is unwilling to nominate a 
preferred QALY (e.g., the HUI with Canadian preferences), the 
fact that within a disease area manufacturers with competing 
products can, by accident or design, opt for a particular multi-
attribute instrument (e.g., some may choose the EQ-5D-3L; 
others the EQ-5D-5L) means that the cost-outcomes claims are 
not comparable. A situation which becomes more 
troublesome when, as NICE has found out, previously accepted 
submissions may have used the EQ-5D-3L. The picture 
becomes even more problematic, if not bizarre, when cost-
per-QALY comparisons are between disease areas where 3 or 
4 generic multi-attribute measures may be jostling for 
attention (e.g., the HUI vs. the nominated cancer generic 
measure (FACT-G). It would seem far easier to fall back on 
disease specific effectiveness measures. At least these would 
make sense to health system decision makers, physicians and 
patients.   
   
Clinical Standards 
There are two further issues that are not addressed in the 
CADTH guidelines that are important for moving from 
imaginary worlds to evaluable claims. These are: (i) evidence 
for the replication of clinical efficacy and safety claims for the 
pivotal phase 2 and phase 3 trials; and (ii) evidence of 
adherence to and persistence with therapy for the new 
product and the comparator. Clearly, attention needs to be 
given to how claims for efficacy and safety as well as 
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comparative adherence and persistence translate to a 
Canadian treating environment, but these are best seen as 
secondary considerations to the reproducibility of claims and 
compliance. As will be discussed below, these issues provide, 
along with claims for treatment effect, key elements in the 
case for protocol driven claims assessment and reporting. 
 
Long-term Uncertainty 
One defense of non-evaluable simulations is that concerns 
with a model or simulation as a ‘sufficient’ representation of 
the real world is taken account of by capturing structural and 
parameter uncertainty. This is not a tenable argument as it 
sidesteps the issue of credible claims and their evaluation. Any 
number of competing lifetime or long-term simulation could 
be constructed with account taken of structural and parameter 
uncertainty, accompanied by the usual tornado diagrams, 
cost-effectiveness acceptability curves and even value of 
information exercises to fill the gaps in the modeled claims. 
However much we try to embellish the modeled imaginary 
world the fact remains that we don’t know, and we will never 
know, whether the announced claims for long-term or lifetime 
comparative therapeutic benefit are right or even if they are 
wrong.  
 
Replication of Clinical Claims 
The guidelines do not, as far as can be ascertained, address the 
issue of the replication of clinical claims. It is all well and good 
to ask for spreadsheet summaries of the relevant RCT data, 
supported, in the absence of head-to-head trials, with network 
meta-analysis and other assessments of comparative efficacy 
(but not effectiveness). Analyses that make a number of 
implicit assumptions regarding acceptance of the quality and 
replicability of the RCTs themselves. There is now an abundant 
literature on irreproducibility in scientific research, including 
Amgen’s attempts to reproduce benchmark studies, Bayer’s 
validation of new drug target claims and an increasing failure 
rate where phase 3 trials attempt to reproduce results 28 29 . At 
the same time, pre-registration of National Heart, Lung and 
Blood Institute trials since 2000 has been associated with a 
decline in the reporting of positive results 30. In a survey 
undertaken by the journal Nature over 70% of researchers 
have tried and failed to reproduce another scientist’s 
experiments and over 50% have failed to reproduce their own 
experiments 31. Given these concerns, it could be argued that 
they place a premium on the need to reproduce clinical claims 
in target Canadian patient populations.  
 
Adherence and Persistence 
A puzzling feature of lifetime reference model claims is the 
neglect of adherence and persistence behavior. The CADTH 
guideline is no exception. Nowhere in the instructions for 
constructing the imaginary reference case is there any 
guidance on including adherence and persistence behavior. 
This appears an odd oversight as the guideline is explicit in the 
requirement for a default lifetime model. If this implies that 
the hypothetical patient cohort are persistent with therapy 
over their lifetime, this flies in the face of decades of 
accumulated evidence which shows that by the end of two 
years from an index prescriptions, probably less than one third 
of patients are persistent with therapy with an even smaller 
proportion maintaining a adherence at a clinically meaningful 
level 32. If this is the case, then to model competing therapies 
assuming full compliance over the lifetime of the patient 
cohort would seem pointless. A default timeline for models of 
two to three years would appear to be more reasonable if the 
intention is to inform decision makers. If more realistic disease 
specific imaginary worlds are mandated by CADTH, then there 
could presumably be a requirement for a systematic review of 
adherence and persistence patterns in that disease area for 
comparator therapies to set the appropriate model timelines. 
 
Recently reported adherence and persistence patterns with 
the new oral anti-coagulants (NOACs) in non-valvular atrial 
fibrillation are an example of short term compliance 33 34 35 36. 
Overall, these estimates suggest that by the end of one year 
after the index prescription persistence with warfarin is in the 
range 60 to 70% with a corresponding NOAC rate of 70 to 80%. 
By the end of year 2, persistence is likely to be 15 to 20% lower. 
Beyond two years is sheer speculation, although it would not 
be unreasonable, given evidence for persistence in other 
chronic disease states to assume that the overwhelming 
majority of patients have discontinued within 3 to 4 years. 
Given the age at which treatment is usually initiated for atrial 
fibrillation, deaths to patients need to be factored in to 
persistence estimates. In the edoxaban pivotal trial, for 
example, 10-8% of patients died before the end of the trial. 
Other recent examples of short-term adherence and 
persistence behavior could be given. Examples would include 
multiple sclerosis where the majority of patients discontinue 
therapy within 2 years and statins in cardiovascular disease 37 
38.  
 
This neglect of adherence and persistence on claims for clinical 
effect and cost-effectiveness, even in the construction of 
imaginary worlds, is puzzling given the attention to the impact 
of private insurance cover on prescription drug utilization in 
Canada. As outpatient prescriptions are outside the scope of 
the Canada Health Act, patients are often faced with significant 
out-of-pocket costs. Policies to meet these costs vary by 
province and the variability in insurance cover. These may 
include policies for ‘catastrophic’ drug costs as well as 
potential support for low income groups where drug-costs 
may consume a significant proportion of income. Law et al, in 
a study utilizing the 2007 Canada Community health survey, 
reported that 1 in 10 Canadians receiving a prescription 
reported cost-related non-adherence 39.  A more recent study 
by Kratzer et al utilizing the 2008 Canadian Community Health 
Survey found, for health cohorts in Ontario with asthma, high 
blood pressure or diabetes, that patients with private 
insurance were more likely to take prescribed drugs than those 
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without 40 . Most recently, with data from the Barriers to Care 
for People with Chronic Health Conditions, Hennessy et al 
reported on the association between the level of out-of-pocket 
spending and the likelihood of cost-related non-adherence 41 . 
The study found that those spending at least 5% of their 
income on prescriptions drugs were more likely to report cost-
related prescription non-adherence than those spending less 
than 5%. Overall, from the various studies the proportion of 
individuals and families with low income and high cost non-
adherence ranged from 5% to 10%. Although Canadian data 
are more limited in their ability to capture adherence and 
persistence behavior from an index prescription than in the 
US, the neglect of the impact of costs on adherence and 
persistence, together with the absence of any attempt to 
factor in likely patterns of adherence and persistence with 
drug classes and disease categories is a major oversight in the 
CADTH guidelines.  
 
Lifetime Costs 
A further puzzling feature is the assumption that, other than 
being discounted at a rate of 1.5% per annum, costs remain 
unchanged over the lifetime of the hypothetical patient 
cohort. This seems an odd requirement if the object is to 
present a model of long term or lifetime costs and benefits. In 
the US, for example, there is ample evidence for pricing 
strategies (price gouging?) by manufacturers for ongoing semi-
annual and annual price increases both over the patent life of 
a drug and beyond. The price increases being typically 
accompanied by co-payment waivers, coupons and other 
discounts to maintain market share. In the case of disease 
modifying treatments (DMTs) in multiple sclerosis a recent 
study of the trend in annualized drug costs for nine DMTs from 
1993 to 2014 found annualized increases ranging from 7.9%. 
to 35.7% 42.  Four of the DMTs had annualized cost increases 
greater than 20% and four in the range 13% to 16.8%. While 
these annualized changes were two to three time bigger than 
in other countries, the potential for annualized price increases 
together with possible price increases in direct medical costs 
should, presumably, be factored into reference case models. 
Lifetime cost increase assumptions may, of course be 
irrelevant if the majority of patients have discontinued therapy 
or report low rates of medication possession within 2 to 3 
years from product listing. 
 
Pipeline Competitors  
It is unlikely, over the lifetime of a patient cohort, that there 
will be no therapies entering the market place to compete with 
and replace existing medications. In the reference case model 
this is not the case. Patients are assumed to remain with the 
indicated drug over their lifetime. Again, this flies in the face 
of evidence for drug turnover in target populations where 
patients are switched to new therapies. This switching may 
reflect a lack of response to the index drug in the treatment 
arm or may involve moving to a combination therapy. Again, 
this appears an odd assumption but one that is, unfortunately, 
driven by the focus on constructing evidence to establish 
credibility rather than on a more practical perspective of 
evaluating claims for feedback to physicians and formulary 
committees.  
 
Next Generation Sequencing 
The likelihood of competitor therapies and therapy 
combinations is also made more likely by the introduction of 
next generation sequencing (NGS) where assay platforms will 
recommend linking sub-groups of patients defined by 
mutation clusters to monotherapy or combination therapies 43 
44. An obvious application is in late stage cancer but there  will 
be applications earlier in the treatment pathway. In these 
scenarios there will be a premium placed on umbrella RCTs and 
tracking evaluable claims and reporting in real time to 
clinicians and health system decision makers on clinical 
outcomes and resource utilization. If a disease area or target 
tumor group is characterized by a distribution of patients by 
mutation cluster then a ‘simplistic’ reference case model is 
hardly a viable basis for therapy choices when multiple 
pathways are involved and patients are individually selected 
for an assay driven intervention. 
 
Redrafting the CADTH  Guidelines 
Although it is unlikely that the CADTH guidelines will be 
redrafted given their recent launch and their commitment to 
the reference case imaginary model paradigm as the basis for 
submissions by manufacturers, the present reference case 
format can be relatively easily modified. As detailed in the 
review of the PBAC guidelines, the modification can be 
accomplished by establishing a cut-off for the modeling of 
clinical and cost-effectiveness claims. The key issue is one of 
supporting feedback to formulary committees. In the Canadian 
case the principal audience would be provincial health 
department, and potentially insurance companies to ensure 
coverage of the product. The proposed cut-off could be two 
years. The modeled claims, whether they are extrapolated 
from clinical trials or represent a de novo model, would 
establish primary clinical and resource utilization endpoints, 
together with the proposed unit cost of the drug. The 
manufacturer’s submission would propose, as part of the 
claims submission, a protocol to evaluate these claims within 
a maximum 2-year timeframe to report back to CADTH. The 
results would be posted to the CADTH website. 
 
As detailed in previous commentaries in this series, together 
with the proposed Minnesota guidelines, the manufacturer is 
responsible for (i) establishing comparative claims for a new 
product that are credible, evaluable and replicable and (ii) 
underwriting a protocol that supports claims evaluation and 
reporting of results. It should be entirely at the manufacturer’s 
discretion as to the choice of clinical and effectiveness 
endpoints. There would be no requirement for a reference 
case or for highly technical, lifetime probabilistic simulations. 
This does not mean that quality of life is necessarily put to one 
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side; rather it has to be considered and justified as a 
meaningful endpoint within a two year timeframe. If there are 
claims for long-term clinical outcomes, then these should be 
assessed via surrogate markers which can be assessed within 
2 years. Focusing on a 2-year timeframe will reinforce claims 
for clinical impact. As the majority of RCTs and attempts to 
make indirect comparisons are typically short term, (with the 
typical RCT not extending beyond 6 months) extrapolating 
clinical benefits from a short timeframe will avoid trying to 
justify longer term, non-evaluable and more uncertain 
benefits.   
 
As recommended in the review of the PBAC guidelines, 
extrapolated or modeled claims should be required to include 
anticipated adherence and persistence behavior. This behavior 
should be required to be reported as part of the study protocol 
with summary measures, for example, to include median time 
to discontinuation of therapy and proportion of patients 
maintaining a medication possession ratio (MPR) or days 
covered by therapy (DCT) > 0.8. An interesting corollary here is 
that if the benefits of a potential new therapy are qualified 
significantly by anticipated adherence and persistence 
behavior, then the manufacturer may propose an intervention 
strategy (funded by the manufacturer) to improve such 
behavior. This could be justified in cost-effectiveness terms 
where the benefits from improved adherence and compliance 
are set against the costs of implementing and monitoring the 
intervention.  
 
CADTH, in redrafting the guidelines to accommodate a 2-year 
timeframe will have to judge the extent to which it makes 
sense to require submissions to incorporate the technical 
modeling standards that characterize the construction and 
reporting of claims from lifetime imaginary worlds. Rejecting 
attempts to model the long-term course of a disease does not 
mean throwing the bathwater out with the baby, but it may 
mean reconsidering the relevance not of simple decision 
frameworks but those frameworks such as Markov processes 
that are designed to support the construction of lifetime 
imaginary worlds. Many of the standards and processes 
detailed in the CADTH guidelines will be relevant to the 
construction of short-term claims models. Just as the 
reference case modeled outcomes can be expressed as total 
costs and outcomes, incremental costs and outcomes and 
incremental cost-effectiveness ratios, so short-term claims can 
be expressed in these terms.  
 
In redrafting the CADTH guidelines the question of evaluating 
claims is not a ‘one-off’. Agreeing a claims assessment protocol 
sets the stage for claims replication. With claims assessment 
within a 2-year timeframe, there is ample scope for evaluating 
feedback from a claims protocol. The protocol could be 
administered in a number of treatment settings to capture 
both heterogeneity in response and its determinants as well as 
more specific claims targeted at sub-populations; evaluations 
which may be better focused on modeled cost-effectiveness 
rather than cost-utility claims. A reassessment of secondary 
outcome claims (e.g., patient satisfaction, comorbidity 
outcomes) and more detailed assessments of the 
determinants of compliance behavior could be a requirement. 
As noted in the review of the PBAC guidelines, CADTH could 
consider sponsoring training programs for protocol 
development as rigorous and well managed protocols for 
either experimental or observational assessments. 
 
Life is, of course, more interesting if clinical and cost-outcomes 
claims fail. Protocols should be judged on their rigor: how high 
is the bar for claims to be accepted?  Is the protocol designed 
to minimize false positives? As noted above, there are ongoing 
concerns over the ability to replicate RCT claims, even when 
the claims are based on two well conducted clinical trials have 
been accepted by regulators. The concern of CADTH should be 
for the implications of including unreproducible or at least 
potentially dodgy clinical data as input to the modeled claims. 
 
Conclusion 
From the perspective of normal science, constructed evidence 
for product impact claims is not acceptable. Regardless of how 
decision modeling is defended by the application of validation 
standards, the treatment of uncertainty and the application of 
value of information techniques, in the last resort the model 
stands or falls on its ability to generate credible, evaluable and 
replicable predictions. The latest version of the CADTH 
guidelines fails to meet this standard. If these guidelines are to 
be seen as credible then they must abandon constructing 
imaginary worlds in favor of evaluable and replicable claims for 
comparative product performance; to reject intelligent design 
in favor of natural selection.  
 
Unfortunately, the imaginary constructs of the status quo may 
be seen as the preferred option. After all, it is what everyone 
else does. Redrafting the guidelines will be seen as unrealistic; 
imposing an unnecessary burden on both manufacturers and 
CADTH. After all, is CADTH in a position to challenge the 
community of appointed pharmacoeconomic scholars? 
Irrespective of the potential benefits to patients and 
physicians, formulary and pricing decisions driven by the 
construction of imaginary worlds may be agreed by the parties, 
after 20years of CADTH submissions, to be mutually 
advantageous and the least troublesome option. Would Sgt. 
Preston, King and Rex approve? 
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